LSMA (The Life Science Manufacturers Association), representing key suppliers to medicines manufacturers, welcomes the European Commission’s publication of the Critical Medicines Act (CMA) proposal and appreciates the opportunity to provide initial feedback. LSMA notes the positive initial alignment of the CMA proposal with our previously expressed priorities, including the emphasis on resilient supply chains, risk-based approaches, and the support of strategic projects to bolster EU manufacturing. LSMA remains committed to ensuring the availability of critical medicines for patients across the European Union and recognizes the importance of robust and resilient supply chains. We are committed to a constructive dialogue with the Commission to ensure the final Regulation achieves our shared goals. LSMA believes that achieving resilience and strategic autonomy requires a broader policy agenda to boost the competitiveness of the wider biotech and pharmaceutical value chains. This should also reflect the need for resilient global supply chains.
